Contents

Ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia (RADIANCE)

March 1, 2014

Clinical trial

RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.

Wolf S, Balciuniene VJ, Laganovska G, Menchini U, Ohno-Matsui K, Sharma T, Wong TY, Silva R, Pilz S, Gekkieva M.

Ophthalmology. 2014 Mar;121(3):682-92.e2.
Full text | Metrics.

Main finding: Over 12 months, individualized ranibizumab treatment was effective in improving and sustaining BCVA in myopic CNV.

 

  • Purpose: To compare the efficacy and safety of ranibizumab 0.5 mg, guided by visual acuity stabilization or disease activity criteria, versus verteporfin photodynamic therapy in patients with myopic choroidal neovascularization.
  • Study type: Randomized controlled trial
  • Condition: Myopic Choroidal Neovascularization

Participants: ≥18 years, active CNV secondary to pathologic myopia, BCVA 20/32-20/320

 

  • n=277

 

Intervention:

 

Group 1: Intravitreal ranibizumab 0.5mg (VA stabilisation criteriae)
Group 2: Intravitreal ranibizumab 0.5mg (Disease activity criteriae)
Group 3: Verteporfin PDT + intravitreal ranibizumab from 3 months onwards (Disease activity criteriae)

Regime in groups 1 and 2: injection on Day 1 and Month 1, then PRN depending on retreatment criteria

Outcome Time period RAN (VA stabilisation) RAN (disease activity) Verteporfin + RAN from 3 months
BCVA change 3 months +10.5 +10.5 +2.2
6 months +11.9 +11.7
12 months +13.8 +14.4 +9.3
number of injections 4 2 2

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed